

### Citations

1. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol: a meta-analysis. *Ann Intern Med* 1993;119:599-605.
2. Ackermann RT, Mulrow CD, Ramirez G et al. Garlic shows promise for improving some cardiovascular risk factors. *Arch Intern Med* 2001;161:813-824.
3. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. *Ann Intern Med* 2000;133:420-429.
4. Silagy C, Neil A. Garlic as a lipid lowering agent—a meta-analysis. *J R Coll Physicians Lond* 1994;28:39-45.
5. Lawson LD, Wang ZJ, Papadimitriou D. Allicin release under simulated gastrointestinal conditions from garlic powder tablets employed in clinical trials on serum cholesterol. *Planta Med* 2001;67:13-18.
6. Lawson LD, Wang ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. *J Agric Food Chem* 2001;49:2592-2599.
7. Fleischauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. *Am J Clin Nutr* 2000;72:1047-1052.
8. El-Bayoumy K, Sinha R, Pinto JT, Rivlin RS. Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds. *J Nutr* 2006;136:864S-869S.
9. Blumenthal M, Busse W, Goldberg A et al. *The Complete German Commission E Monographs*. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
10. ESCOP. *Allii Sativi Bulbus*. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:14-25.
11. WHO. *Bulbus Allii Sativi*. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:16-33.
12. McKenna D, Jones K, Hughes K, Humphrey S. *Garlic*. Botanical Medicines. 2nd ed. Binghampton: Haworth Press; 2002:375-409.
13. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. *Ann Pharmacother* 2000;34:1478-1482.
14. Steiner M, Li W. Aged garlic extract, a modulator of cardiovascular risk factors: a dose-finding study on the effects of AGE on platelet functions. *J Nutr* 2001;131:980S-984S.
15. Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. *J Nutr* 2000;130:2662-2665.
16. Kiesewetter H, Jung F, Pindur G et al. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. *Int J Clin Pharmacol Ther Toxicol* 1991;29:151-155.
17. Kiesewetter H, Jung F, Jung EM et al. Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack. *Eur J Clin Pharmacol* 1993;45:333-336.
18. German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. *Br J Urol* 1995;76:518.
19. Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. *Neurosurgery* 1990;26:880-882.
20. Burnham BE. Garlic as a possible risk for postoperative bleeding. *Plast Reconstr Surg* 1995;95:213.
21. Macan H, Uykipang R, Alconcel M et al. Aged garlic extract may be safe for patients on warfarin therapy. *J Nutr* 2006;136:793S-795S.
22. Siegel G, Walter A, Engel S et al. [Pleiotropic effects of garlic]. *Wien Med Wochenschr* 1999;149:217-224.
23. Thomson M, Al-Qattan KK, Bordia T, Ali M. Including garlic in the diet may help lower blood glucose, cholesterol, and triglycerides. *J Nutr* 2006;136:800S-802S.
24. Budoff M. Aged garlic extract retards progression of coronary artery calcification. *J Nutr* 2006;136:741S-744S.
25. Yeh YY, Yeh SM. Homocysteine-lowering action is another potential cardiovascular protective factor of aged garlic extract. *J Nutr* 2006;136:745S-749S.
26. Weiss N, Ide N, Abahji T et al. Aged garlic extract improves homocysteine-induced endothelial dysfunction in macro- and microcirculation. *J Nutr* 2006;136:750S-754S.
27. Borek C. Garlic reduces dementia and heart-disease risk. *J Nutr* 2006;136:810S-812S.
28. Lash JP, Cardoso LR, Mesler PM et al. The effect of garlic on hypercholesterolemia in renal transplant patients. *Transplant Proc* 1998;30:189-191.
29. Teyssier C, Guenot L, Suschetet M, Siess MH. Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. *Drug Metab Dispos* 1999;27:835-841.

## Citations and Reference Literature: Garlic

30. Jin L, Baillie TA. Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. *Chem Res Toxicol* 1997;10:318-327.
31. Wargovich MJ. Diallylsulfide and allylmethylsulfide are uniquely effective among organosulfur compounds in inhibiting CYP2E1 protein in animal models. *J Nutr* 2006;136:832S-834S.
32. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. *J Clin Pharm Ther* 2000;25:165-175.
33. Zhou S, Koh HL, Gao Y et al. Herbal bioactivation: the good, the bad and the ugly. *Life Sci* 2004;74:935-968.
34. Loizou GD, Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. *Hum Exp Toxicol* 2001;20:321-327.
35. Gurley BJ, Gardner SF, Hubbard MA et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. *Clin Pharmacol Ther* 2002;72:276-287.
36. Davenport D, Wargovich M. Modulation of cytochrome P450 enzymes by organosulfur compounds from garlic. *Food Chem Toxicol* 2005.
37. Yang CS, Chhabra SK, Hong JY, Smith TJ. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. *J Nutr* 2001;131:1041S-1045S.
38. Taubert D, Glockner R, Muller D, Schomig E. The garlic ingredient diallyl sulfide inhibits cytochrome P450 2E1 dependent bioactivation of acrylamide to glycidamide. *Toxicol Lett* 2006;164:1-5.
39. Wang EJ, Li Y, Lin M et al. Protective effects of garlic and related organosulfur compounds on acetaminophen-induced hepatotoxicity in mice. *Toxicol Appl Pharmacol* 1996;136:146-154.
40. Milner JA. Preclinical perspectives on garlic and cancer. *J Nutr* 2006;136:827S-831S.
41. Herman-Antosiewicz A, Singh SV. Signal transduction pathways leading to cell cycle arrest and apoptosis induction in cancer cells by *Allium* vegetable-derived organosulfur compounds: a review. *Mutat Res* 2004;555:121-131.
42. Gurley BJ, Gardner SF, Hubbard MA et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. *Drugs Aging* 2005;22:525-539.
43. Marchand LL, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. *Cancer Epidemiol Biomarkers Prev* 1999;8:495-500.
44. Milner JA. Molecular targets for bioactive food components. *J Nutr* 2004;134:2492S-2498S.
45. Markowitz JS, Devane CL, Chavin KD et al. Effects of garlic (*Allium sativum* L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. *Clin Pharmacol Ther* 2003;74:170-177.
46. Foster BC, Foster MS, Vandenhoek S et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. *J Pharm Pharm Sci* 2001;4:176-184.
47. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. *Biochem Biophys Res Commun* 2005;327:866-870.
48. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes p450. *J Nutr* 2006;136:806S-809S.
49. Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. *J Nutr* 2001;131:1000S-1005S.
50. Manyike PT, Kharasch ED, Kalhorn TF, Slaterry JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. *Clin Pharmacol Ther* 2000;67:275-282.
51. Dooley TP. Molecular biology of the human phenol sulfotransferase gene family. *J Exp Zool* 1998;282:223-230.
52. Court MH, Duan SX, von Moltke LL et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. *J Pharmacol Exp Ther* 2001;299:998-1006.
53. Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. *Semin Liver Dis* 2003;23:227-237.
54. Lee WM. Acute liver failure in the United States. *Semin Liver Dis* 2003;23:217-226.
55. Hu JJ, Yoo JS, Lin M et al. Protective effects of diallyl sulfide on acetaminophen-induced toxicities. *Food Chem Toxicol* 1996;34:963-969.
56. Hattori A, Yamada N, Nishikawa T et al. Protective effect of ajoene on acetaminophen-induced hepatic injury in mice. *Biosci Biotechnol Biochem* 2001;65:2555-2557.
57. Sumioka I, Matsura T, Yamada K. Therapeutic effect of S-allylmercaptocysteine on acetaminophen-induced liver injury in mice. *Eur J Pharmacol* 2001;433:177-185.
58. Sumioka I, Matsura T, Kasuga S et al. Mechanisms of protection by S-allylmercaptocysteine against acetaminophen-induced liver injury in mice. *Jpn J Pharmacol* 1998;78:199-207.
59. Lin MC, Wang EJ, Patten C et al. Protective effect of diallyl sulfone against acetaminophen-induced hepatotoxicity in mice. *J Biochem Toxicol* 1996;11:11-20.

## Citations and Reference Literature: Garlic

60. Zhao C, Shichi H. Prevention of acetaminophen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine. *J Ocul Pharmacol Ther* 1998;14:345-355.
61. Kalantari H, Salehi M. The protective effect of garlic oil on hepatotoxicity induced by acetaminophen in mice and comparison with N-acetylcysteine. *Saudi Med J* 2001;22:1080-1084.
62. Gwilt PR, Lear CL, Tempero MA et al. The effect of garlic extract on human metabolism of acetaminophen. *Cancer Epidemiol Biomarkers Prev* 1994;3:155-160.
63. Briggs WH, Xiao H, Parkin KL et al. Differential inhibition of human platelet aggregation by selected *Allium* thiosulfonates. *J Agric Food Chem* 2000;48:5731-5735.
64. Ali M, Bordia T, Mustafa T. Effect of raw versus boiled aqueous extract of garlic and onion on platelet aggregation. *Prostaglandins Leukot Essent Fatty Acids* 1999;60:43-47.
65. Apitz-Castro R, Badimon JJ, Badimon L. Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation. *Thromb Res* 1992;68:145-155.
66. Apitz-Castro R, Badimon JJ, Badimon L. A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vivo porcine experimental model. *Thromb Res* 1994;75:243-249.
67. Ariga T, Tsuji K, Seki T et al. Antithrombotic and antineoplastic effects of phyto-organosulfur compounds. *BioFactors* 2000;13:251-255.
68. Chan K-c, Hsu C-c, Yin M-c. Protective effect of three diallyl sulphides against glucose-induced erythrocyte and platelet oxidation, and ADP-induced platelet aggregation. *Thromb Res* 2002;108:317-322.
69. Qi R, Liao F, Inoue K et al. Inhibition by diallyl trisulfide, a garlic component, of intracellular Ca(2+) mobilization without affecting inositol-1,4, 5-trisphosphate (IP[3]) formation in activated platelets. *Biochem Pharmacol* 2000;60:1475-1483.
70. Rendu F, Brohard-Bohn B, Pain S et al. Thiosulfonates inhibit platelet aggregation and microparticle shedding at a calpain-dependent step. *Thromb Haemost* 2001;86:1284-1291.
71. Allison GL, Lowe GM, Rahman K. Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. *J Nutr* 2006;136:782S-788S.
72. Allison GL, Lowe GM, Rahman K. Aged garlic extract may inhibit aggregation in human platelets by suppressing calcium mobilization. *J Nutr* 2006;136:789S-792S.
73. Kiesewetter H, Jung F, Mrowietz C et al. Effects of garlic on blood fluidity and fibrinolytic activity: a randomised, placebo-controlled, double-blind study. *Br J Clin Pract Suppl* 1990;69:24-29.
74. Bordia A, Verma SK, Srivastava KC. Effect of garlic (*Allium sativum*) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. *Prostaglandins Leukot Essent Fatty Acids* 1998;58:257-263.
75. Gadkari JV, Joshi VD. Effect of ingestion of raw garlic on serum cholesterol level, clotting time and fibrinolytic activity in normal subjects. *J Postgrad Med* 1991;37:128-131.
76. Apitz-Castro R, Escalante J, Vargas R, Jain MK. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dipyridamole on human platelets. *Thromb Res* 1986;42:303-311.
77. Harenberg J, Giese C, Zimmermann R. Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia. *Atherosclerosis* 1988;74:247-249.
78. Teweleit S, Kuschel U, Hippus M et al. [Manifestation and prevention of adverse drug reactions (ADR) in the pharmacotherapy of cardiovascular diseases]. *Med Klin* 2001;96:442-450.
79. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *BMJ* 2004;329:15-19.
80. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. *Ann Oncol* 2006;17:1586-1591.
81. Ewer M, Benjamin R. Cardiotoxicity of chemotherapeutic drugs. In: Perry M, ed. *The Chemotherapy Source Book*. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2001:458-468.
82. Kojima R, Toyama Y, Ohnishi ST. Protective effects of an aged garlic extract on doxorubicin-induced cardiotoxicity in the mouse. *Nutr Cancer* 1994;22:163-173.
83. Dwivedi C, John LM, Schmidt DS, Engineer FN. Effects of oil-soluble organosulfur compounds from garlic on doxorubicin-induced lipid peroxidation. *Anticancer Drugs* 1998;9:291-294.
84. Thabrew MI, Samarawickrema NA, Chandrasena LG, Jayasekera S. Protection by garlic against Adriamycin-induced alterations in the oxido-reductive status of mouse red blood cells. *Phytother Res* 2000;14:215-217.
85. Mukherjee S, Banerjee SK, Maulik M et al. Protection against acute Adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF- $\alpha$  expression. *BMC Pharmacol* 2003;3:16.
86. Borek C. Antioxidant health effects of aged garlic extract. *J Nutr* 2001;131:1010S-1015S.

## Citations and Reference Literature: Garlic

87. Arora A, Seth K, Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. *Carcinogenesis* 2004;25:941-949.
88. Chen C, Kong A-NT. Dietary chemopreventive compounds and ARE/EpRE signaling. *Free Radical Biol Med* 2004;36:1505-1516.
89. Gebhardt R. Multiple inhibitory effects of garlic extracts on cholesterol biosynthesis in hepatocytes. *Lipids* 1993;28:613-619.
90. Qureshi AA, Abuirmeileh N, Din ZZ et al. Inhibition of cholesterol and fatty acid biosynthesis in liver enzymes and chicken hepatocytes by polar fractions of garlic. *Lipids* 1983;18:343-348.
91. Gebhardt R. Inhibition of cholesterol biosynthesis by a water-soluble garlic extract in primary cultures of rat hepatocytes. *Arzneimittelforschung* 1991;41:800-804.
92. Liu L, Yeh YY. S-alk(en)yl cysteines of garlic inhibit cholesterol synthesis by deactivating HMG-CoA reductase in cultured rat hepatocytes. *J Nutr* 2002;132:1129-1134.
93. Kumar RV, Banerji A, Kurup CK, Ramasarma T. The nature of inhibition of 3-hydroxy-3-methylglutaryl CoA reductase by garlic-derived diallyl disulfide. *Biochim Biophys Acta* 1991;1078:219-225.
94. Singh DK, Porter TD. Inhibition of sterol 4 $\alpha$ -methyl oxidase is the principal mechanism by which garlic decreases cholesterol synthesis. *J Nutr* 2006;136:759S-764S.
95. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. *J Hypertens* 1994;12:463-468.
96. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10: a review of animal and human publications. *Biofactors* 2003;18:101-111.
97. Lang A, Lahav M, Sakhnini E et al. Allicin inhibits spontaneous and TNF- $\alpha$  induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells. *Clin Nutr* 2004;23:1199-1208.
98. Horie T, Matsumoto H, Kasagi M et al. Protective effect of aged garlic extract on the small intestinal damage of rats induced by methotrexate administration. *Planta Med* 1999;65:545-548.
99. Horie T, Awazu S, Itakura Y, Fuwa T. Alleviation by garlic of antitumor drug-induced damage to the intestine. *J Nutr* 2001;131:1071S-1074S.
100. Khosla P, Karan RS, Bhargava VK. Effect of garlic oil on ethanol induced gastric ulcers in rats. *Phytother Res* 2004;18:87-91.
101. Piscitelli SC, Burstein AH, Welden N et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. *Clin Infect Dis* 2002;34:234-238.
102. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. *Br J Clin Pharmacol* 2003;55:199-202.
103. Patel J, Buddha B, Dey S et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. *Am J Ther* 2004;11:262-277.
104. Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. *J Pharmacol Exp Ther* 2004;308:941-948.
105. Gisolf EH, van Heeswijk RP, Hoetelmans RW, Danner SA. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. *AIDS* 2000;14:801-805.
106. Sunter WH. Warfarin and garlic [letter]. *Pharmacol J* 1991;246:722.
107. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. *Br J Clin Pharmacol* 2001;52:587-595.
108. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med* 1998;158:2200-2211.
109. Rozenfeld V, Sisca T, Callahan A, Crain J. Double-blind, randomized, placebo-controlled trial of aged garlic extract in patients stabilized on warfarin therapy [poster]. American Society of Clinical Pharmacists, Mid-year Clinical Meeting. Las Vegas; 2000.
110. Pathak A, Leger P, Bagheri H et al. Garlic interaction with fluindione: a case report. *Therapie* 2003;58:380-381.
111. Comets E, Pousset F, Mentre F et al. Prediction of fluindione maintenance dosage hampered by large intraindividual variability. *Ther Drug Monit* 2000;22:668-675.
112. Loebstein R, Yonath H, Peleg D et al. Interindividual variability in sensitivity to warfarin—nature or nurture? *Clin Pharmacol Ther* 2001;70:159-164.
113. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. *BMJ* 2002;325:828-831.
114. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med* 1994;121:676-683.
115. Borgert CJ, Borgert SA, Findley KC. Synergism, antagonism, or additivity of dietary supplements: application of theory to case studies. *Thromb Res* 2005;117:123-132; discussion 145-151.
116. Marder VJ. The interaction of dietary supplements with antithrombotic agents: scope of the problem. *Thromb Res* 2005;117:7-13; discussion 39-42.

## Citations and Reference Literature: Garlic

117. Ciplea AG, Richter KD. The protective effect of *Allium sativum* and *crataegus* on isoprenaline-induced tissue necroses in rats. *Arzneimittelforschung* 1988;38:1583-1592.
118. Saxena KK, Gupta B, Kulshrestha VK et al. Effect of garlic pretreatment on isoprenaline-induced myocardial necrosis in albino rats. *Indian J Physiol Pharmacol* 1980;24:233-236.
119. Banerjee SK, Sood S, Dinda AK et al. Chronic oral administration of raw garlic protects against isoproterenol-induced myocardial necrosis in rat. *Comp Biochem Physiol C Toxicol Pharmacol* 2003;136:377-386.
120. Brinker F. *Herb Contraindications and Drug Interactions*. 3rd ed. Sandy, Ore: Eclectic Medical Publications; 2001.
121. Martin N, Bardisa L, Pantoja C et al. Experimental cardiovascular depressant effects of garlic (*Allium sativum*) dialysate. *J Ethnopharmacol* 1992;37:145-149.
122. Martin N, Bardisa L, Pantoja C et al. Anti-arrhythmic profile of a garlic dialysate assayed in dogs and isolated atrial preparations. *J Ethnopharmacol* 1994;43:1-8.
123. Martin N, Bardisa L, Pantoja C et al. Involvement of calcium in the cardiac depressant actions of a garlic dialysate. *J Ethnopharmacol* 1997;55:113-118.
124. Jain RC, Vyas CR. Garlic in alloxan-induced diabetic rabbits. *Am J Clin Nutr* 1975;28:684-685.
125. Mathew PT, Augusti KT. Studies on the effect of allicin (diallyl disulphide-oxide) on alloxan diabetes. I. Hypoglycaemic action and enhancement of serum insulin effect and glycogen synthesis. *Indian J Biochem Biophys* 1973;10:209-212.
126. Zhang XH, Lowe D, Giles P et al. Gender may affect the action of garlic oil on plasma cholesterol and glucose levels of normal subjects. *J Nutr* 2001;131:1471-1478.
127. Huang CN, Horng JS, Yin MC. Antioxidative and antiglycative effects of six organosulfur compounds in low-density lipoprotein and plasma. *J Agric Food Chem* 2004;52:3674-3678.
128. Ahmad MS, Ahmed N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. *J Nutr* 2006;136:796S-799S.